Adjuvant capecitabine did not improve outcomes for patients with early triple-negative breast cancer

(American Association for Cancer Research) Treating patients who had early-stage triple-negative breast cancer with the chemotherapy agent capecitabine after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news